Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: dazodalibep, dapirolizumab pegol, ravagalimab +3 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 341 | 0.91 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 4138
Sealed predictions
- CD40LG in dopamine neurons, braak-0.06 (p 0.873) → -0.04 (p 0.912)receipt 4145
Swarm cases
receipt 4145: CD40LG in dopamine neurons, braak
- power
- full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.834, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 4; without severely affected donors -0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD40LG in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts